View Item 

Show simple item record

MALIGNANT SOMATOSTATINOMA PRESENTING WITH DIABETIC KETOACIDOSIS
dc.contributor.authorJackson, J. A.en_US
dc.contributor.authorRaju, B. U.en_US
dc.contributor.authorFachnie, J. D.en_US
dc.contributor.authorMellinger, R. C.en_US
dc.contributor.authorJanakiraman, N.en_US
dc.contributor.authorLloyd, Ricardo V.en_US
dc.contributor.authorVinik, Aaron I.en_US
dc.date.accessioned2010-06-01T22:36:06Z
dc.date.available2010-06-01T22:36:06Z
dc.date.issued1987-05en_US
dc.identifier.citationJACKSON, J. A.; RAJU, B. U.; FACHNIE, J. D.; MELLINGER, R. C.; JANAKIRAMAN, N.; LLOYD, R. V.; VINIK, A. I. (1987). "MALIGNANT SOMATOSTATINOMA PRESENTING WITH DIABETIC KETOACIDOSIS." Clinical Endocrinology 26(5): 609-621. <http://hdl.handle.net/2027.42/75579>en_US
dc.identifier.issn0300-0664en_US
dc.identifier.issn1365-2265en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75579
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2822297&dopt=citationen_US
dc.description.abstractHigh circulating levels of somatostatin (SRIF) were detected in a patient with a metastatic tumour after development of diabetic ketoacidosis (DKA). Fasting insulin and C-peptide levels were markedly suppressed, but plasma glucagon was not suppressed below normal. Progressive cachexia ensued; at autopsy a poorly differentiated non-small cell neuroendocrine carcinoma metastatic to liver was found. Small gallstones were noted. Electron microscopy of tumour tissue showed neurosecretory granules and tonofilament bundles. Immunohis-tochemical staining of tumour cells was diffusely positive for carcinoembryonic antigen, bombesin-like immunoreactivity, and calcitonin with focal immuno-reactivity for SRIF, serotonin, neuron-specific enolase, chromogranin, and epithelial membrane antigen. Column chromatography of plasma and tumour extract revealed five or more peaks of material with SRIF-like immunoreactivity (SRIF-LI): predominantly SRIF-28 and intermediates in tumour extract, and SRIF-14 and an intermediate between SRIF-28 and SRIF-14 in plasma. DKA in this case of somatostatinoma syndrome may reflect differential effects of tumour production of larger molecular weight SRIF forms on insulin and glucagon secretion.en_US
dc.format.extent1032604 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights1987 Blackwell Scientific Publicationsen_US
dc.titleMALIGNANT SOMATOSTATINOMA PRESENTING WITH DIABETIC KETOACIDOSISen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumThe Departments of Internal Medicine and Pathology, Henry Ford Hospital, Detroit, MI 48201, USA, and the Departments of Pathology and Internal Medicine and Surgery, University of Michigan, Ann Arbor, MI 48109, USAen_US
dc.identifier.pmid2822297en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75579/1/j.1365-2265.1987.tb00817.x.pdf
dc.identifier.doi10.1111/j.1365-2265.1987.tb00817.xen_US
dc.identifier.sourceClinical Endocrinologyen_US
dc.identifier.citedreferenceAbe, K., Yamaguchi, K., Adachi, I., Suzuki, M., Kumura, S., Shimada, A., Maruno, K. & Yanaihara, N. ( 1984 ) Production of gastrin-releasing peptide (bombesin) by tumors. In Endocrinology: Proceedings of the 7 th International Congress of Endocrinology ( eds F. Labrie & L. Proulx ), pp. 77 – 80. Excerpta Medica, Amsterdam, New York, Oxford.en_US
dc.identifier.citedreferenceAder, M. & Bergman, R.N. ( 1985 ) Direct effect of somatostatin infusion to increase glucose clearance in dogs. In Program and Abstracts of the Sixty-Seventh Annual Meeting of The Endocrine Society. Baltimore, Maryland. Abstract 102.en_US
dc.identifier.citedreferenceAxelrod, L., Bush, M.A., Hirsch, H.J. & Loo, S.W.H. ( 1981 ) Malignant somatostatinoma: Clinical features and metabolic studies. Journal of Clinical Endocrinology and Metabolism, 52, 886 – 896.en_US
dc.identifier.citedreferenceBrazeau, P., Ling, N., Esch, F., Bohlen, P., Benoit, P., Benoit, R. & Guillemin, R. ( 1981 ) High biological activity of the synthetic replicates of somatostatin-28 and somatostatin-25. Regulatory Peptides, 1, 255 – 264.en_US
dc.identifier.citedreferenceConlon, J.M., McCarthy, D., Krejs, G. & Unger, R.H. ( 1981 ) Characterization of somatostatin-like components in the tumors and plasma of a patient with somatostatinoma. Journal of Clinical Endocrinology and Metabolism, 52, 66 – 73.en_US
dc.identifier.citedreferenceGalmiche, J.P., Colin, R., DuBois, P.M., Chayvialle, J.A., Descos, F., Paulin, C. & Geffroy, Y. ( 1978 ) Calcitonin secretion by a pancreatic somatostatinoma (letter). New England Journal of Medicine, 299, 1252.en_US
dc.identifier.citedreferenceGanda, O.P., Weir, G.C., Soeldner, J.S., Legg, M.A., Chick, W.L., Patel, Y.C., Ebeid, A.M., Gabbay, K.H. & Reichlin, S. ( 1977 ) Somatostatinoma: A somatostatin-containing tumor of the endocrine pancreas. New England Journal of Medicine, 296, 963 – 967.en_US
dc.identifier.citedreferenceGerich, J.E., Lorenzi, M., Bier, D.M., Schneider, V., Tsalikian, E., Karam, J.H. & Forsham, P.H. ( 1975a ) Prevention of human diabetic ketoacidosis by somatostatin: Evidence for an essential role of glucagon. New England Journal of Medicine, 292, 985 – 989.en_US
dc.identifier.citedreferenceGerich, J.E., Lovinger, P. & Grodsky, G.M. ( 1975b ) Inhibition by somatostatin of glucagon and insulin release from the perfused rat pancreas in response to arginine, isoproterenol and theophylline: evidence for a preferential effect on glucagon secretion. Endocrinology, 96, 749 – 754.en_US
dc.identifier.citedreferenceGerlock Jr, A.J., Muhletaler, C.A., Halter, S. & Goncharenko, V. ( 1979 ) Pancreatic somatostatinoma: Histologic, clinical, and angiographic features. American Journal of Roentgenology, 133, 939 – 943.en_US
dc.identifier.citedreferenceGhose, R.R. & Gupta, S.K. ( 1981 ) Oat cell carcinoma of bronchus presenting with somatostatinoma syndrome. Thorax, 36, 550 – 551.en_US
dc.identifier.citedreferenceGould, V.E., Linnoila, R.I., Memoli, V.A. & Warren, W.H. ( 1983 ) Neuroendocrine components of the bronchopulmonary tract: Hyperplasias, dysplasias, and neoplasms. Laboratory Investigation, 49, 519 – 537.en_US
dc.identifier.citedreferenceHsu, S.M., Raine, L. & Fanger, H. ( 1981 ) A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. American Journal of Clinical Pathology, 75, 732 – 738.en_US
dc.identifier.citedreferenceIshikawa, N. & Hamad A. S. ( 1976 ) Association of medullary carcinoma of the thyroid with carcinomembryonic antigen. British Journal of Cancer, 34, 111 – 115.en_US
dc.identifier.citedreferenceIto, S., Yamada, Y., Iwanaga, T., Kaneko, H. & Shibata, A. ( 1982 ) Somatostatin-28-like immunoreactivity in normal and tumor tissue from duodenum and pancreas. Acta Endocrinologica, 101, 421 – 427.en_US
dc.identifier.citedreferenceKeller, U., Chiasson, J-L., Liljenquist, J.E., Cherrington, A.D., Jennings, A.S. & Crofford, O.B. ( 1977 ) The roles of insulin, glucagon, and free fatty acids in the regulation of ketogenesis in dogs. Diabetes, 26, 040 – 1051.en_US
dc.identifier.citedreferenceKelly, T.R. ( 1983 ) Pancreatic somatostatinoma. American Journal of Surgery, 146, 671 – 673.en_US
dc.identifier.citedreferenceKothary, P.C., Vinik, A.I., Owyang, C. & Fiddian-Green, R.G. ( 1983 ) Immunochemical studies of molecular heterogeneity of cholecystokinin in duodenal perfusates and plasma in humans. Journal of Biological Chemistry, 258, 2856 – 2863.en_US
dc.identifier.citedreferenceKrejs, G.J., Orci, L., Conlon, J.M., Ravazzola, M., Davis, G.R., Raskin, P., Collins, S.M., McCarthy, D.M., Baetens, D., Rubenstein, A., Aldor, T.A.M. & Unger, R.H. ( 1979 ) Somatostatinoma syndrome: Biochemical, morphologic and clinical features. New England Journal of Medicine, 301, 285 – 292.en_US
dc.identifier.citedreferenceLarsson, L-I., Hirsch, M.A., Holst, J.J., Ingdmansson, S., Kuhl, C, Lindkaer Jensen, S., Lundqvist, G., Rehfeld, J.F. & Schwartz, T.W. ( 1977 ) Pancreatic somatostatinoma: Clinical features and physiological implications. Lancet, i, 666 – 668.en_US
dc.identifier.citedreferenceLloyd, R. V. & Wilson, B.S. ( 1983 ) Specific endocrine tissue marker defined by a monoclonal antibody. Science, 111, 628 – 630.en_US
dc.identifier.citedreferenceLloyd, R.V., Mervak, T., Warner, T.F.C.S., Schmidt, K. & Wilson, B.S. ( 1984 ) Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms. American Journal of Surgical Pathology, 8, 607 – 614.en_US
dc.identifier.citedreferenceLokich, J.J. ( 1982 ) Plasma CEA levels in small cell lung cancer: Correlation with stage, distribution of metastases, and survival. Cancer, 50, 2154 – 2156.en_US
dc.identifier.citedreferenceMandarino, L., Stenner, D., Blanchard, W., Nissen, S., Gerich, J., Ling, N., Brazeau, P., Bohlen, P., Esch, F. & Guillemin, R. ( 1981 ) Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion. Nature, 291, 76 – 77.en_US
dc.identifier.citedreferenceMcDowell, E.M., Wilson, T.S. & Trump, B.F. ( 1981 ) Atypical endocrine tumors of the lung. Archives of Pathology and Laboratory Medicine, 105, 20 – 28.en_US
dc.identifier.citedreferenceMcGarry, J.D. & Foster, D.W. ( 1980 ) Regulation of hepatic fatty acid oxidation and ketone body production. Annual Review of Biochemistry, 49, 395 – 420.en_US
dc.identifier.citedreferenceMiyauchi, A., Onishi, T., Morimoto, S., Shin-Ichiro, T., Matsuzuka, F., Kuma, K., Masazumi, M. & Kumahara, Y. ( 1984 ) Relation of doubling time of plasma calcitonin level to prognosis and recurrence of medullary thyroid carcinoma. Annals of Surgery, 199, 461 – 466.en_US
dc.identifier.citedreferenceNakanome, C, Koizumi, M., Fujiya, H., Akai, H., Toyota, T., Goto, Y., Kameyama, J., Miyakawa, K. & Hanew, K. ( 1984 ) Somatostatinoma syndrome accompanied by overproduction of pancreatic polypeptide. Tohoku Journal of Experimental Medicine, 142, 201 – 210.en_US
dc.identifier.citedreferenceO'Connor, D.T., Burton, D. & Deftos, L.J. ( 1983 ) Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. Journal of Clinical Endocrinology and Metabolism, 57, 1084 – 1086.en_US
dc.identifier.citedreferencePatel, Y.C., Ganda, O.M. & Benoit, R. ( 1983 ) Pancreatic somatostatinoma: Abundance of somato-statin-28 (1–12) -like immunoreactivity in tumor and plasma. Journal of Clinical Endocrinology and Metabolism, 57, 1048 – 1053.en_US
dc.identifier.citedreferencePenman, E. Lowry, P.J., Wass, J.A.H., Marks, V., Dawson, A.M., Besser, G.M. & Rees, L.H. ( 1980 ) Molecular forms of somatostatin in normal subjects and in patients with pancreatic somatostatinoma. Clinical Endocrinology, 12, 611 – 620.en_US
dc.identifier.citedreferencePipeleers, D., Somers, G., Gepts, W., De Nutte, N. & De Vroede, M. ( 1979 ) Plasma pancreatic hormone levels in a case of somatostatinoma: Diagnostic and therapeutic implications. Journal of Clinical Endocrinology and Metabolism, 49, 572 – 579.en_US
dc.identifier.citedreferencePrice, J., Nieuwenhuijzen Kruseman, A.C., Doniach, I., Howlett, T.A., Besser, G.M. & Rees, L.H. ( 1985 ) Bombesin-like peptides in human endocrine tumors: Quantitation, biochemical characterization, and secretion. Journal of Clinical Endocrinology and Metabolism, 60, 1097 – 1103.en_US
dc.identifier.citedreferenceReynoso, G., Chu, T.M., Holyoke, D., Cohen, E., Nemoto, T., Wang, J.J., Chuang, J., Guinan, P. & Murphy, G.P. ( 1972 ) Carcinoembryonic antigen in patients with different cancers. Journal of the American Medical Association, 220, 361 – 365.en_US
dc.identifier.citedreferenceSaad, M.F., Fritsche Jr, H.A. & Samaan, N.A. ( 1984 ) Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. Journal of Clinical Endocrinology and Metabolism, 58, 889 – 894.en_US
dc.identifier.citedreferenceSchusdziarra, V., Zyznar, E., Rouiller, D., Boden, G., Brown, J.C., Arimura, A. & Unger, R.H. ( 1980 ) Splanchnic somatostatin: A hormonal regulator of nutrient homeostasis. Science, 207, 530 – 532.en_US
dc.identifier.citedreferenceSchusdziarra, V. Grube, D., Seifert, H., Galle, J., Etzrodt, H., Beischer, W., Haferkamp, O. & Pfeiffer, E.F. ( 1983 ) Somatostatinoma syndrome: Clinical, morphological and metabolic features and therapeutic aspects. Klinische Wochenschrift, 61, 681 – 689.en_US
dc.identifier.citedreferenceSimpson, S., Vinik, A.I., Marangos, P.J. & Lloyd, R.V. ( 1984 ) Immunohistochemical localization of neuron-specific enolase in gastroentero-pancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase. Cancer, 54, 1364 – 1369.en_US
dc.identifier.citedreferenceSive, A.A., Vinik, A.I. & Levitt, N.S. ( 1980 ) Adrenergic modulation of human pancreatic polypeptide (hPP) release. Gastroenterology, 79, 665 – 672.en_US
dc.identifier.citedreferenceStarr, J.I. & Rubenstein, A.H. ( 1974 ) Insulin, proinsulin and C-peptide. In Methods of Hormone Radioimmunoassay ( eds B. M. Jaffe & H. R. Behrman ), pp. 289 – 315. Academic Press, New York.en_US
dc.identifier.citedreferenceStrodel, W.E., Vinik, A.I., Joffe, B.M., Eckhauser, F.E. & Thompson, N.W. ( 1984 ) Substance P in localization of carcinoid tumors. Journal of Surgical Oncology, 27, 106 – 111.en_US
dc.identifier.citedreferenceSusini, C, Esteve, J.P., Vaysse, N., Pradayrol, L. & Ribet, A. ( 1980 ) Somatostatin-28: Effects on exocrine pancreatic secretion in conscious dogs. Gastroenterology, 79, 720 – 724.en_US
dc.identifier.citedreferenceTannenbaum, G.S., Ling, N. & Brazeau, P. ( 1982 ) Somatostatin-28 is longer acting and more selective than somatostatin-14 on pituitary and pancreatic hormone release. Endocrinology, 111, 101 – 107.en_US
dc.identifier.citedreferenceTashjian Jr, A.H. ( 1969 ) Immunoassay of calcitonin. 1. The method and its serological specificity. Endocrinology, 84, 140 – 148.en_US
dc.identifier.citedreferenceTran, V.T., Beal, M.F. & Martin, J.B. ( 1985 ) Two types of somatostatin receptors differentiated by cyclic somatostatin analogs. Science, 228, 492 – 495.en_US
dc.identifier.citedreferenceUnger, R.H. ( 1977 ) Editorial. Somatostatinoma. New England Journal of Medicine, 296, 998 – 1000.en_US
dc.identifier.citedreferenceVinik, A.I., Levitt, N.S., Pimstone, B.L. & Wagner, L. ( 1981a ) Peripheral plasma somatostatin-like immunoreactive responses to insulin hypoglycemia and a mixed meal in healthy subjects and in noninsulin-dependent maturity-onset diabetics. Journal of Clinical Endocrinology and Metabolism, 52, 330 – 337.en_US
dc.identifier.citedreferenceVinik, A.I., Gaginella, T.S., O'Dorisio, T.M., Shapiro, B. & Wagner, L. ( 1981b ) The distribution and characterization of somatostatin-like immunoreactivity in epithelial cells, submucosa, and muscle of the rat stomach and intestine. Endocrinology, 109, 1921 – 1926.en_US
dc.identifier.citedreferenceVinik, A.I., Strodel, W.E. & O'Dorisio, T.M. ( 1984 ) Endocrine tumors of the gastroenteropancreatic axis. In Diagnosis and Management of Endocrine-related tumors ( eds R. J. Santen & A. Manni ), pp. 235 – 304. Martinus Nijhoff, Boston.en_US
dc.identifier.citedreferenceYesner, R. ( 1978 ) Spectrum of lung cancers and ectopic hormones. In Pathology Annual 13 ( part 1 ) ( eds S. C. Sommers & P. P. Rosen ), pp. 217 – 240. Appleton-Century-Crofts, New York.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2265.1987.tb00817.x.pdf
Size:
1008.KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.